
Lexaria Bioscience Corp. Common Stock
LEXX
LEXX: Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio.
moreShow LEXX Financials
Recent trades of LEXX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by LEXX's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on LEXX's company Twitter account
Number of mentions of LEXX in WallStreetBets Daily Discussion
Recent insights relating to LEXX
Recent picks made for LEXX stock on CNBC
ETFs with the largest estimated holdings in LEXX
Flights by private jets registered to LEXX